Abstracts tagged "Rheumatoid Factor"

Abstract Number: 1578 • 2015 ACR/ARHP Annual Meeting
Serum Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Associated with Subclinical Interstitial Lung Disease in the Multi-Ethnic Study of Atherosclerosis: A Population-Based Study
Elana J. Bernstein¹, R. Graham Barr², John H.M. Austin³, Steven M. Kawut⁴, Ganesh Raghu⁵, Jessica L. Sell⁶, Eric A. Hoffman⁷, John D. Newell Jr.⁸, Jubal R. Watts Jr.⁹, P. Hrudaya Nath¹⁰, Sushil K. Sonavane⁹, Joan M. Bathon¹, Darcy S. Majka¹¹ and David J. Lederer², ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Medicine, Columbia University College of Physicians & Surgeons, New York, NY, ³Radiology, Columbia University College of Physicians & Surgeons, New York, NY, ⁴Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA, ⁵University of Washington, Seattle, WA, ⁶Columbia University College of Physicians & Surgeons, New York, NY, ⁷University of Iowa, Iowa City, IA, ⁸Radiology, University of Iowa, Iowa City, IA, ⁹Radiology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰University of Alabama at Birmingham, Birmingham, AL, ¹¹Division of Rheumatology, Northwestern University, Chicago, IL
Background/Purpose: Approximately 30% of adults diagnosed with interstitial lung disease (ILD) have an underlying established autoimmune disease. Based on the strong links between autoimmunity and…
Abstract Number: 1607 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Factor Is Associated with the Distribution of Hand Joint Destruction in a Dose-Dependent Manner
Chikashi Terao¹, Noriyuki Yamakawa², Koichiro Yano³, I.M. Markusse⁴, Katsunori Ikari³, Shinji Yoshida³, Moritoshi Furu⁵, Motomu Hashimoto⁵, Hiromu Ito⁵, Takao Fujii⁶, Koichiro Ohmura⁷, Kosaku Murakami⁷, Meiko Takahashi², Masahide Hamaguchi⁸, Yasuharu Tabara², Atsuo Taniguchi³, Shigeki Momohara³, Soumya Raychaudhuri⁹, Cornelia F. Allaart¹⁰, Hisashi Yamanaka¹¹, Tsuneyo Mimori¹² and Fumihiko Matsuda¹³, ¹Departments of Genetics and Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴LUMC, Leiden, Netherlands, ⁵Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Dept of Rheum/Clinical Immun, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁷Dept of Rheum & Clinical Immun, Kyoto Univ Grad School of Med, Kyoto, Japan, ⁸Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan, ⁹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ¹⁰Rheumatology, LUMC, Leiden, Netherlands, ¹¹Tokyo Women's Medical University, Tokyo, Japan, ¹²Dept of Rheum & Clinical Immun, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ¹³Genomic Center, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease leading to joint destruction. Although many studies have addressed correlates associated with the speed of joint destruction,…
Abstract Number: 1658 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Affects the Efficacy of First Biological Treatment in RA
Yoshikazu Ogawa¹, Nobunori Takahashi², Koji Funahashi², Shuji Asai³, Toki Takemoto³, Tatsuo Watanabe³, Nobuyuki Asai², Naoki Ishiguro⁴ and Toshihisa Kojima², ¹orthopedic surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ³Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Rheumatoid factor (RF) is considered an important factor in diagnosing rheumatoid arthritis (RA). The association between the treatment efficacy of biological agents and RF…
Abstract Number: 1740 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibodies and Inflammatory Bowel Disease
Jaita Mukherjee¹, Maria Mouyis¹, Kavina Shah¹, Mohammad Mahdi Saeidinejad¹, Ayesha Akbar² and Shahir Hamdulay¹, ¹Rheumatology, Northwick Park Hospital, Middlesex, United Kingdom, ²Gastroenterology, Northwick Park Hospital, Middlesex, United Kingdom
Background/Purpose: Enteropathic arthropathy refers to the pattern of inflammatory arthritis seen in association with gastrointestinal pathology. Arthritis in the presence of inflammatory bowel disease can…
Abstract Number: 2257 • 2015 ACR/ARHP Annual Meeting
Decline of Lung Function Is Associated with the Presence of Rheumatoid Factor in Korean Health Screening Subjects without Clinically Apparent Lung Diseases
Jiwon Hwang¹, Jae-Uk Song², Hyungjin Kim³, Hyemin Jeong⁴, Yeong Hee Eun⁵, Chan Hong Jeon⁶, Ji-Min Oh⁷, Jaejoon Lee⁴, Hoon-Suk Cha⁸, Eun-Mi Koh⁵ and Joong Kyong Ahn⁹, ¹Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Internal Medicine, Kangbuk Samsung Hospital, Seoul, South Korea, ³Department of medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ⁷Anyang SAM Hospital, Anyang, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁹Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Rheumatoid factor (RF) is an autoantibody directed against the Fc component of IgG. It is present in approximately 70-80% of rheumatoid arthritis (RA) patients…
Abstract Number: 2372 • 2015 ACR/ARHP Annual Meeting
Timing of Onset and Cluster with Other Manifestations Influence the Spectrum of Arthritis in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International, Retrospective Study
Alberto Sifuentes Giraldo¹, Carlo Alberto Scirè², Santos Castañeda³, Laura Nuño⁴, Francisco Javier Lopez Longo⁵, Julia Martínez-Barrio⁵, Franco Franceschini⁶, Ilaria Cavazzana⁶, Paolo Airò⁷, Elena Bartoloni Bocci⁸, Javier Bachiller Corral⁹, Rossella Neri¹⁰, Simone Barsotti¹¹, Roberto Caporali¹², Carlomaurizio Montecucco¹³, Marcello Govoni¹⁴, Renato La Corte¹⁴, Federica Furini¹⁴, Florenzo Iannone¹⁵, Margherita Giannini¹⁶, Enrico Fusaro¹⁷, Simone Parisi¹⁸, Giuseppe Paolazzi¹⁹, Giovanni Barausse¹⁹, Raffaele Pellerito²⁰, Alessandra Russo²⁰, Lesley Ann Saketkoo²¹, Norberto Ortego-Centeno²², Luca Quartuccio²³, Christof Specker²⁴, Andreas Schwarting²⁵, Kostantinos Triantafyllias²⁶, Carlo Selmi²⁷, Fausto Salaffi²⁸, Marco Amedeo Cimmino²⁹, Annamaria Iuliano³⁰, Fabrizio Conti³¹, Gianluigi Baiocchi³², Elena Bravi³³, Veronica Codullo¹², Anna Ghirardello³⁴, Trinitario Pina³⁵, Miguel Angel Gonzalez-Gay³⁵, Lorenzo Cavagna¹³ and AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group, ¹Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ²Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, ⁵Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁷Rheumatology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁸Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, ⁹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹⁰Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹¹Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹²Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ¹³Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ¹⁴UOC Reumatologia, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy, ¹⁵Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ¹⁶DIM, Rheumatology Unit, Bari, Italy, ¹⁷Department of Rheumatology, Città della Salute e della Scienza, Torino, Italy, ¹⁸Department of Rheumatology, Città Della Salute e della Scienza, Torino, Italy, ¹⁹Rheumatology Unit, Santa Chiara Hospital, Trento, Italy, ²⁰Division of Rheumatology, Mauriziano Hospital, Turin, Italy, ²¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²²Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, ²³Clinic of Rheumatology, Department of Medical and Biological Sciences (DSMB), Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ²⁴Department for Rheumatology and Clinical Immunology, St. Josef Krankenhaus, University Clinic, Essen, Germany, ²⁵Department of Internal Medicine, Rheumatology and Clinical Immunology, University Hospital Johannes-Gutenberg, Mainz, Germany, ²⁶ACURA Rheumatology Center, Bad Kreuznach, Germany, ²⁷Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ²⁸Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ²⁹Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy, ³⁰Osp. San Camillo, Roma, Italy, ³¹Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ³²Rheumatology Unit, Department of Internal Medicine, S.Maria Hospital –IRCCS, Reggio Emilia, Italy, ³³Internal Medicine, Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy, ³⁴Department of Medicine-DIMED, University of Padova, Padova, Italy, ³⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: arthritis, myositis and interstitial lung disease (ILD) are reported in up to 90% of patients affected by antisynthetase syndrome (ASSD) and thus represent the…
Abstract Number: 2441 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3η Is Present in JIA and Is Not Associated with RF+ Polyarthritis
Alan M. Rosenberg¹, Walter Maksymowych², Yuan Gui³ and Anthony Marotta³, ¹Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Augurex Life Sciences Corp., Vancouver, BC, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a collective term used to denote clinically discrete subtypes, which include: Enthesitis-related arthritis, Oligoarthritis, Polyarthritis, Psoriatic arthritis, Systemic arthritis…
Abstract Number: 447 • 2015 ACR/ARHP Annual Meeting
Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status
Arthur G Pratt¹, Ben Hargreaves², Dennis W Lendrem², Osman Aslam² and John D Isaacs², ¹Institute of Cellular Medicine (Musculoskeletal Research Group), National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Despite a proliferation of early arthritis (EA) clinics intended to expedite the diagnosis of rheumatoid arthritis (RA), patients continue to experience substantial and multifactorial…
Abstract Number: 2450 • 2015 ACR/ARHP Annual Meeting
Examination of the Clinical Significance of 14-3-3 Eta in Juvenile Idiopathic Arthritis
Lance Feller¹, Austin M. Dalrymple², Paul Tuttle IV³, Reema H. Syed³, Peri Pepmueller¹ and Terry Moore⁴, ¹Rheumatology, Saint Louis University, St. Louis, MO, ²Pediatric Rheumatology, St. Louis University, St. Louis, MO, ³IM-Rheumatology, Saint Louis University, St. Louis, MO, ⁴Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO
Background/Purpose: 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…
Abstract Number: 2021 • 2014 ACR/ARHP Annual Meeting
The Association Between Rheumatoid Factor and Cardiovascular Disease in Healthy Adults
Chisun Min¹, Mitsumasa Kishimoto¹, Gautam A. Deshpande², Shunya Kaneshita¹, Masei Suda¹, Yuri Ohara¹, Yoichiro Haji¹, Ryo Rokutanda¹, Yasuhiro Suyama¹, Hisanori Shimizu¹, Tokutaro Tsuda¹, Ken-ichi Yamaguchi¹, Akira Takeda³, Yukio Matsui¹ and Masato Okada¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Center for Clinical Epidemiology, St. Luke's Life Science Instutute, Tokyo, Japan, ³Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan
Background/Purpose Rheumatoid arthritis (RA) has been shown to be a risk factor for cardiovascular disease (CVD). Both elevated rheumatoid factor (RF) and anti-citrullinated protein antibodies…
Abstract Number: 1560 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Is a Predictor of Osteoporosis in Patients with Psoriatic Arthritis
Frank Behrens^1,2, Michaela Koehm^2,3, Eva C. Scharbatke⁴, Bianca Wittig⁵, Marc Schmalzing⁴, Holger Gnann⁶, H M Lorenz⁷, Diamant Thaci⁸ and Harald Burkhardt^1,9, ¹Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, ²Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ³Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ⁴Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ⁵Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁷University Hospital Heidelberg, Heidelberg, Germany, ⁸Comprehensive Center of Inflammation Medicine, University Hospital Schleswig Holstein Campus Luebeck, Lübeck, Germany, ⁹Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany
Background/Purpose Osteoporosis is an important comorbidity in patients with rheumatic diseases, but risk factors for osteoporosis in Psoriatic Arthritis (PsA) patients have not been explored. …
Abstract Number: 1404 • 2014 ACR/ARHP Annual Meeting
Presence and Significance of Anti-CCP Antibody in Patients with Interstitial Lung Disease with and without Clinically Apparent Rheumatoid Arthritis
Muhammad Imran¹, Shanley O'brien², Mark Hamblin³ and Mehrdad Maz⁴, ¹Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Internal Medicine, Kansas University Medical Center, Kansas city, MO, ³Pulmonary and Critical Care Medicine, ILD Clinic, Kansas University Medical Center, Kansas city, MO, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Interstitial lung disease (ILD) can be idiopathic or associated with underlying etiologies including rheumatoid arthritis (RA). The purpose of this study is to determine…
Abstract Number: 1054 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not ACPA, Is Associated with Disease Activity in Rheumatoid Arthritis
Daniel Aletaha¹, Farideh Alasti² and Josef Smolen³, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose To investigate the associations of rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPA) with rheumatoid arthritis (RA) disease activity.Methods We analyzed the association…
Abstract Number: 453 • 2014 ACR/ARHP Annual Meeting
In a Periodontal Disease Cohort without RA, Indeterminate or Low-Positive Anti-CCP-2 Antibodies Are Associated with Multiple Distinct ACPA
Jerry A. Molitor¹, Bryan S. Michalowicz², Ryan T. Demmer³, Jane H. Buckner⁴, Mark H. Wener⁵ and William H. Robinson⁶, ¹Rheumatology, University of Minnesota, Minneapolis, MN, ²Department of Developmental and Surgical Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ³Epidemiology, Columbia Univ. Mailman School of Public Health, New York, NY, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Rheumatology & Lab Med, University of Washington, Seattle, WA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Periodontal disease (PD) and RA share the risk factors HLA DR B1 shared epitope (SE) and tobacco exposure (TE). PD may represent a risk…
Abstract Number: 408 • 2014 ACR/ARHP Annual Meeting
14-3-3η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA
D. van Schaardenburg¹, Mairead Murphy², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Jan van Breemen Research Institute, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose We have previously reported pilot data that patients who are only positive for 14-3-3η auto-antibodies (AAb) and negative for the 14-3-3η protein have a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].